Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

TP53 mutations are ubiquitous in high‐grade serous ovarian carcinomas (HGSOC), and the presence of TP53 mutation discriminates between high and low‐grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Köbel, Martin, Piskorz, Anna M, Lee, Sandra, Lui, Shuhong, LePage, Cecile, Marass, Francesco, Rosenfeld, Nitzan, Mes Masson, Anne‐Marie, Brenton, James D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091634/
https://www.ncbi.nlm.nih.gov/pubmed/27840695
http://dx.doi.org/10.1002/cjp2.53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091634/
https://www.ncbi.nlm.nih.gov/pubmed/27840695
http://dx.doi.org/10.1002/cjp2.53

Ejemplares similares